People ask about these two together constantly, usually phrased as which one is better. That question doesn't quite work, because they don't do the same job. Here's what each one is, in plain terms, and why they turn up as a pair so often.
Proxiva Analytical DeskCertificate review, purity and identity testing
Key takeaways
- They aren't competitors. Ipamorelin and CJC-1295 no-DAC act on two different receptors, and researchers pair them precisely because the mechanisms are separate.
- Ipamorelin is a ghrelin receptor agonist. CJC-1295 no-DAC is a GHRH analogue. Different doors, same building.
- "No-DAC" matters. The DAC version has a Drug Affinity Complex attached that extends its half-life dramatically. No-DAC does not, and behaves very differently.
- Because they're so often used together, a pre-blended version exists as a single vial.
- Both are short peptides with ordinary handling requirements — nothing unusual about storage or reconstitution.
The short answer
Neither one is better. They're not alternatives.
Ipamorelin works on the ghrelin receptor. CJC-1295 no-DAC works on the GHRH receptor. Those are two separate receptors on the same cells in the pituitary. Hitting one is a different signal from hitting the other.
That's the whole reason they show up as a pair in research protocols. You're not picking a winner — you're looking at two inputs to the same system, which is a more interesting experiment than either one alone. It's also why somebody sells them pre-mixed.
What Ipamorelin actually is
It's a pentapeptide. Five amino acids. That's small, even by peptide standards.
It's classified as a growth hormone secretagogue, which means it prompts release rather than supplying anything itself. Specifically it's a ghrelin receptor agonist — it binds the same receptor that ghrelin does.
The thing Ipamorelin is known for in the literature is selectivity. Earlier compounds in this class were messier, triggering release of other hormones alongside the intended one. Ipamorelin is comparatively clean, and that's why it displaced a lot of the older material in research use.
Standard research fill is 5mg. Proxiva lists it as Ipamorelin.
What CJC-1295 no-DAC is, and why the suffix matters
CJC-1295 is an analogue of growth hormone releasing hormone. It's a modified fragment of the natural GHRH sequence, engineered so it doesn't fall apart as fast as the native peptide does.
Now the suffix. This trips people up more than anything else about the compound.
| Version | What's attached | Half-life behaviour |
|---|---|---|
| CJC-1295 with DAC | A Drug Affinity Complex that binds serum albumin | Dramatically extended — days |
| CJC-1295 no-DAC | Nothing attached | Short — closer to native GHRH |
The DAC is a chemical group that latches onto albumin in the blood, which stops the peptide being cleared quickly. It's a genuinely large difference — not a minor variant. No-DAC is sometimes called Mod GRF 1-29, which is another name that causes confusion in listings.
If you order one expecting the other, the compound will not behave the way you planned. Check the mass spectrometry result on the certificate; the two have different molecular weights.
Why they're used together
Two separate receptors, both on somatotroph cells in the anterior pituitary.
A GHRH analogue like CJC-1295 no-DAC signals through one pathway. A ghrelin receptor agonist like Ipamorelin signals through another. Research examining the interaction between the two pathways needs both present — you can't study an interaction with one input.
That's the practical reason the combined 10mg vial exists. One reconstitution instead of two, one set of handling steps, one less place to make an error.
The catch is that a blend fixes the ratio at whatever the manufacturer decided. Separate vials of Ipamorelin and CJC-1295 no-DAC let you set that yourself. If the ratio is a variable in your work, buy them separately. If it isn't, the blend saves you a step.
Researchers working across the same general area often also stock Tesamorelin, which is another GHRH analogue, for comparison.
What "selectivity" means in practice
Selectivity comes up constantly in descriptions of Ipamorelin, and it's worth unpacking because the word gets used loosely.
A receptor agonist binds a receptor and triggers it. The problem is that binding is rarely perfectly clean — a compound shaped to fit one receptor will often fit others too, just less well. When that happens you get effects you didn't ask for, running alongside the one you wanted.
Earlier growth hormone secretagogues had exactly this problem. They worked, but they also prompted release of other hormones at the same time. For research that's a serious nuisance: if three things move at once, attributing an observed change to any one of them becomes guesswork.
Ipamorelin's reputation rests on being comparatively clean in this respect. Fewer off-target effects means fewer confounds, which means results that are easier to attribute. That's the entire practical argument for it over older material in the class — not that it's stronger, but that it's tidier.
It's a good illustration of why "which is more potent" is usually the wrong question about research compounds. Potency is easy to adjust. Specificity is not.
Handling — nothing unusual here
Both are short peptides and neither needs special treatment.
- Lyophilised powder stays cold, dry and out of light in its sealed vial.
- Reconstitute with bacteriostatic water if the vial will be punctured more than once.
- Run the diluent down the vial wall, not straight onto the powder.
- Swirl, don't shake.
- Refrigerate afterwards, write the date on the vial, and don't re-freeze it.
The full procedure is in our guide to reconstituting research peptides, and longer-term considerations are in storage and stability.
What to check before buying either
Same checks as anything else, with one extra emphasis.
The extra emphasis is mass spectrometry, because of the DAC problem. HPLC purity tells you the vial is clean. It does not tell you whether you got the DAC version or the no-DAC version — those look identical on a purity trace and completely different on a mass spec.
Beyond that: batch number on the certificate matching the vial, purity at 98% or better, a chromatogram image rather than just a number, a named testing lab, and a residual solvent panel. Our COA guide covers each field.
On price, convert to cost per milligram before comparing anything. A 5mg vial and a 10mg vial at similar prices are not similar purchases. This applies across the catalogue equally — BPC-157, TB-500, Semax, Selank, MOTS-c, Epithalon, GHK-Cu, NAD+, Glutathione and blends like KLOW all price differently per milligram than their sticker prices suggest.
Where the names cause trouble
More than most compounds, this pair suffers from naming problems that show up as real ordering errors.
CJC-1295 no-DAC is also sold as Mod GRF 1-29, and as CJC-1295 DAC-free, and occasionally just as "modified GRF". These generally refer to the same thing, but a buyer searching one term may not find listings using another, and a seller using several interchangeably may not be distinguishing carefully themselves.
The DAC version is sometimes listed simply as "CJC-1295" with no suffix at all, on the reasoning that DAC was the original. Someone ordering "CJC-1295" expecting the short-acting version can receive the long-acting one, and the difference is not subtle.
Ipamorelin has fewer aliases but is regularly grouped with other secretagogues — GHRP-2, GHRP-6, hexarelin — in ways that blur which is which. They belong to the same class and act on the same receptor, but they are distinct molecules with different selectivity profiles.
The defence is the same in both cases: order by molecular identity, not by product name, and confirm against the mass-spectrometry result on the certificate. The mass is unambiguous where the name is not.
A note on the wider class
Both compounds sit inside a broader family, and knowing the shape of it makes the individual comparisons easier to place.
Growth hormone secretagogues divide roughly into two groups by receptor. GHRH analogues act on the GHRH receptor, and include CJC-1295 in both its forms and Tesamorelin. Ghrelin receptor agonists act on the ghrelin receptor, and include Ipamorelin along with the older GHRP compounds.
The practical consequence is that comparisons within a group are meaningful in a way comparisons across groups are not. Ipamorelin versus another ghrelin receptor agonist is a real question about selectivity and profile. Ipamorelin versus a GHRH analogue is a category difference, which is why the pairing exists in the first place.
Frequently asked questions
Which is better, Ipamorelin or CJC-1295?
Neither — they act on different receptors and aren't alternatives to each other. Ipamorelin is a ghrelin receptor agonist; CJC-1295 no-DAC is a GHRH analogue. They're used together because the mechanisms are separate.
What does no-DAC mean?
DAC is a Drug Affinity Complex that binds serum albumin and dramatically extends half-life. The no-DAC version has no such group attached and clears far faster. They are meaningfully different compounds.
Is CJC-1295 no-DAC the same as Mod GRF 1-29?
Those names are commonly used for the same compound, which causes confusion in listings. Confirm identity via the mass-spectrometry result rather than the product name.
Should I buy them separately or as a blend?
A blend is one reconstitution and one less error source, but fixes the ratio. Separate vials let you set the ratio yourself. If ratio is a variable in your work, buy separately.
Does either need special handling?
No. Both follow standard peptide practice — cold and dark while lyophilised, bacteriostatic water for multi-draw reconstitution, refrigerate afterwards, never re-freeze.
Why is Ipamorelin described as selective?
Because it triggers comparatively few off-target effects compared with earlier compounds in its class. For research that matters — fewer simultaneous changes means an observed result is easier to attribute to the intended mechanism.
Related research compounds
Further reading
Research use only. All products referenced on this page are sold strictly for laboratory and research purposes. They are not drugs, foods, cosmetics, or medical devices, and they are not intended to diagnose, treat, cure, or prevent any disease. They are not for human or veterinary consumption. Handling should be performed only by qualified individuals in an appropriate laboratory setting.